<DOC>
	<DOCNO>NCT02374385</DOCNO>
	<brief_summary>Background : Ebola virus infect killed people , mostly Africa . In 2014 , Ebola virus affect several thousand people . There approved effective way treat prevent Ebola . Researchers try develop vaccine . Objectives : To study anti-Ebola vaccine VSV ZEBOV ( BPSC1001 ) see safe . Also , see affect people 's immune system . Eligibility : - Healthy men woman age 18-65 . They must chronic medical condition require medicine . They must healthcare worker , animal care worker , childcare worker , must household contact compromise immune system , pregnant , age 5 year . Design : - Participants screen medical history , physical exam , blood test . - Participants randomly assign get vaccine placebo . - At visit 1 ( vaccination ) , vital sign take blood drawn . The vaccine placebo inject upper arm muscle . - Participants return clinic 11 time next 6 month . Participants blood drawn every study visit . Their mouth swab urine test least four time vaccination . - For 14 day vaccination , participant write temperature , symptom , redness injection site . They bring booklet study visit . All visit take place Canadian Center Vaccinology , Dalhousie University/IWK Health Centre , Halifax , NS .</brief_summary>
	<brief_title>Phase I Trial Assess Safety , Tolerability Immunogenicity Ebola Virus Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult male nonpregnant , nonlactating female , age 18 65 ( inclusive ) time screen Have provide write informed consent screen Free clinically significant health problem , determine pertinent medical history clinical examination prior entry study Available , able , willing participate study visit procedure Males female willing practice abstinence sexual intercourse , willing use effective method contraception , least 30 day prior vaccination study end . If female partner NOT childbearing potential , couple require use condom , without adjunctive contraception . For study , woman consider childbearing potential unless postmenopausal ( â‰¥ 1 year without menses ) surgically sterilize ( tubal ligation , bilateral oophorectomy , hysterectomy ) Effective contraception define contraceptive method failure rate le 1 % per year use consistently correctly applicable , accordance product label , example : Male condom PLUS : Oral contraceptive , either combined progestogen alone , injectable progestogen , implant etonogestrel levonorgestrel , oestrogenic vaginal ring , percutaneous contraceptive patch , intrauterine device intrauterine system Be willing minimize blood body fluid exposure others 7 day vaccination Use effective barrier prophylaxis , latex condom , penetrative sexual intercourse Avoiding sharing needle , razor , toothbrush Avoiding openmouth kiss History prior infection filovirus prior participation filovirus vaccine trial History prior infection VSV receipt VSV vectored vaccine Is healthcare worker direct contact patient Has household contact ( HHC ) immunodeficient , HIVpositive , pregnant , unstable medical condition , age 5 year Is childcare worker direct contact child 5 year age younger Directly prepare food food industry History employment industry involve contact ruminant animal , veterinary science , potential exposure VSV History employment activity involve potential contact filoviruses History severe local systemic reaction vaccination history severe allergic reaction Known allergy component BPSC1001 vaccine product Receipt investigational product 30 day prior enrollment ongoing participation another clinical trial involve investigational product Receipt license vaccine within 30 day plan study immunization Ability observe possible local reaction eligible injection site ( deltoid region ) , opinion investigator , unacceptably obscure due physical condition permanent body art Acute chronic , clinically significant psychiatric , hematologic , pulmonary , cardiovascular , hepatic renal functional abnormality determine investigator base medical history , physical exam , ECG , and/or laboratory screen test Any baseline laboratory screen test outside acceptable range define protocol ALT , AST , creatinine , hemoglobin , platelet count , total white blood cell count , urine protein , urine occult blood , urine glucose Any serologic evidence hepatitis B C infection Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection , cytotoxic therapy previous 5 year , and/or diabetes Any chronic active neurologic disorder , include migraine , seizure , epilepsy , exclude single febrile seizure child Have active malignancy history metastatic hematologic malignancy Suspected know alcohol and/or illicit drug abuse within past 5 year Moderate severe illness and/or fever great 100.4 F within one week prior vaccination Pregnant lactate female , female intend become pregnant study period Administration immunoglobulins and/or blood product within 120 day precede study entry plan administration study period History blood donation within 60 day enrollment plan donate within study period Administration chronic ( defined 14 day ) immunosuppressant immune modify drug within 6 month study entry For corticosteroid , mean prednisone , equivalent , great equal 0.5 mg/kg/day Intranasal topical steroid allow Unwilling allow storage use blood future vaccine research Any significant finding opinion investigator would increase risk individual adverse outcome participating study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>